News Conference News ACC 2021 Sacubitril/Valsartan Lowers Triglycerides in HFpEF: PARAGON-HF Yael L. Maxwell May 16, 2021
News Conference News AHA 2020 Simple Tech Empowers HF Patients, Boosting Health: EPIC-HF and MyROAD L.A. McKeown November 18, 2020
News Conference News AHA 2020 Empagliflozin Improves Cardiac Function, Exercise Capacity in Nondiabetic HFrEF Todd Neale November 16, 2020
News Conference News AHA 2020 Modest Gains With Omecamtiv Mecarbil in Chronic HFrEF: GALACTIC-HF Todd Neale November 13, 2020
News Conference News HFSA 2020 EMBRACE HF: Empagliflozin Cuts PA Pressure in HF With or Without Diabetes L.A. McKeown October 09, 2020
News Conference News ESC 2020 PARALLAX: Mixed Results for Sacubitril/Valsartan in HFpEF Todd Neale August 30, 2020
News Conference News ESC 2020 EMPEROR-Reduced: Empagliflozin Cuts Hospitalizations, CV Mortality in HFrEF Michael O'Riordan August 28, 2020
News Conference News ACC 2020 A Win for Vericiguat in High-Risk Chronic HF Patients: VICTORIA Michael O'Riordan March 28, 2020
News Conference News AHA 2019 Sex Differences, EF Thresholds Probed for Sacubitril/Valsartan in Heart Failure Shelley Wood November 22, 2019
News Conference News AHA 2019 Dapagliflozin Has Benefits Across Heart Failure Subgroups Todd Neale November 17, 2019
News Conference News HFSA 2019 Virtual Doctor Visits Reduce Missed Appointments After HF Hospitalizations: ViV-HF L.A. McKeown September 23, 2019
News Conference News HFSA 2019 New PROVE-HF Data May Reassure Clinicians of Sacubitril/Valsartan Benefit in HFrEF L.A. McKeown September 18, 2019
News Conference News HFSA 2019 DEFINE-HF: Dapagliflozin Improves Function and QoL, but Not Biomarkers, in HFrEF L.A. McKeown September 16, 2019
News Conference News ESC 2019 Primary Prevention ICDs Still Render Better Survival, Even in Modern HFrEF Patients Todd Neale September 13, 2019
News Conference News ESC 2019 Beta-blockers Safe, Effective for HFrEF Patients With Renal Dysfunction: Meta-analysis Yael L. Maxwell September 12, 2019
News Conference News ESC 2019 DAPA-HF Details: Dapagliflozin Slashes HF Outcomes, Even in Nondiabetics Shelley Wood September 01, 2019
News Conference News ESC Heart Failure 2019 Rivaroxaban Cuts Major Stroke Risk in COMMANDER HF Post Hoc Analysis Shelley Wood May 26, 2019
News Conference News HRS 2019 BeAT-HF: Baroreflex Activation Therapy Improves Outcomes in Subset of HF Patients Todd Neale May 15, 2019
News Conference News ACC 2019 New DECLARE-TIMI 58 Data Shine a Light on Diabetes Patients Most Likely to Benefit From Dapagliflozin Shelley Wood March 26, 2019